Publication 3ème trim 2025

Détails
Clics : 15

Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

3ème trim 2025

  1. Bailey GE, Azadi J, Russell JO, Cochand-Priollet B, Maleki Z. Ultrasound- guided thyroid fine-needle aspiration and concurrent core needle biopsy: A comparative study with practical clinical scenarios. Am J Clin Pathol. 2025 Sep 9;164(3):500-512. doi: 10.1093/ajcp/aqaf079. PMID: 40713932. Bailey-Ultrasound-guided_thyroid2025.pdf

  2. Beddok A, Baptiste Morvan J, Boudin L, Da Silva Ribeiro Mota A, Dutheil P, Guilbert P, Rozenblum L, Theresette Guilbert A, Zalzali M, Marcy PY, Thariat J. The role of external beam radiation therapy in thyroid cancer management: A Scoping Review. Int J Radiat Oncol Biol Phys. 2025 Sep 26:S0360-3016(25)06313-8. doi: 10.1016/j.ijrobp.2025.09.050. Epub ahead of print. PMID: 41016492. Voir fichier : Beddok-The_role_of_external_beam2025.pdf

  3. Ciappuccini R, Saguet-Rysanek V, Bompain PA, Balosso J, Leman R, Castera L, Bardet S. NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases. Eur Thyroid J. 2025 Oct 6;14(5):e250100. doi: 10.1530/ETJ-25-0100. PMID: 40990092; PMCID: PMC12508307. Voir fichier : Ciappuccini- NSD32025

  4. Do Cao C, Desailloud R, Topolinski H, Crépin M, Flament C, Leteurtre E, Cardot-Bauters C, Frénois F, Ait-Yahya É, Bonte F, Leclerc J, Pigny P. Analysis of genetic predisposition to familial non-medullary thyroid cancer by whole genome sequencing. Ann Endocrinol (Paris). 2025 Sep 10;86(5):102456. doi: 10.1016/j.ando.2025.102456. Epub ahead of print. PMID: 40939960. Voir fichier : DoCao-Analysis_of_genetic2025.pdf

  5. Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, Brose MS. Patient- Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid Cancer. Thyroid. 2025 Aug 18. doi: 10.1177/10507256251367352. Epub ahead of print. PMID: 40828665. Voir fichier : Elisei-Patient-Reported2025.pdf

  6. Gauduchon T, Varnier R, Cassier PA. Selpercatinib in the treatment of thyroid cancer. Future Oncol. 2025 Aug;21(20):2585-2592. doi: 10.1080/14796694.2025.2531575. Epub 2025 Jul 10. PMID: 40638871; PMCID: PMC12344793. Voir fichier : pdf

  7. Klein M, Klein AJC, Raem AM, Garrelfs N, Fischer HJ, Hölzle F, Wermker K. Next-Generation Sequencing Reveals the Potential Role of RET Protooncogene in Metastasis Progression in Medullary Thyroid Cancer. Curr Issues Mol Biol. 2025 Jul 18;47(7):560. doi: 10.3390/cimb47070560. PMID: 40729029; PMCID: PMC12293786. Voir fichier : Klein-Next-Generation2025.pdf

  8. Nappi C, Cras Y, Lamartina L, Deandreis D. Dosimetry in Advanced Thyroid Cancer: A Piece of a Puzzle? Endocrinol Metab Clin North Am. 2025 Sep;54(3):407-418. doi: 10.1016/j.ecl.2025.03.011. Epub 2025 Apr 28. PMID: 40716895. Voir fichier : Nappi-Dosimetry2025.pdf

  9. Porcelli T, De Stefano MA, Luongo C, Schlumberger M, Salvatore D. The unique signature of tyrosine kinase inhibitor-induced hypothyroidism. Lancet Diabetes Endocrinol. 2025 Sep;13(9):803-812. doi: 10.1016/S2213-8587(25)00193-7. Epub 2025 Jul 14. PMID: 40675173. Voir fichier : Porcelli-The_unique_signature2025.pdf

  10. Puygrenier P, Deniziaut G, Gaujoux S, Vinh JYKD, Buffet C, Menegaux F, Chereau N. Comparison of Oncocytic and Follicular Carcinoma of the Thyroid Without Initial Distant Metastasis. World J Surg. 2025 Sep;49(9):2449-2456. doi: 10.1002/wjs.70018. Epub 2025 Jul 25. PMID: 40714958; PMCID: PMC12435605. Voir fichier : Puygrenier-Comparison_of_Oncocytic2025.pdf

  11. Sajous C, Lasolle H, Decaussin-Petrucci M, Lopez J, Borson Chazot F. Prolonged response to lenvatinib in a poorly differentiated thyroid carcinoma with leptomeningeal carcinomatosis. Ann Endocrinol (Paris). 2025 Sep 10;86(5):102458. doi: 10.1016/j.ando.2025.102458. Epub ahead of print. PMID: 40939961. Voir fichier : Sajou-Prolonged_response2025.pdf

  12. Taprogge J, Murray I, Sharman H, Gape P, Leek F, Abreu C, Vávrová L, Newbold K, Wong KH, Luster M, Verburg FA, Schurrat T, Vija L, Courbon F, Vallot D, Bardiès M, Schumann S, Eberlein U, Lassmann M, Flux G. Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. Eur Thyroid J. 2025 Jul 1;14(4):e250097. doi: 10.1530/ETJ-25-0097. PMID: 40532046; PMCID: PMC12229276. Voir fichier : Taprogge-Predictive_factors2025.pdf
  13.